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Disease progression modelling 
from preclinical Alzheimer’s disease 
(AD) to AD dementia
Soo Hyun Cho1,2,17, Sookyoung Woo3,17, Changsoo Kim4, Hee Jin Kim1,5, Hyemin Jang1,5, 
Byeong C. Kim2, Si Eun Kim6, Seung Joo Kim7, Jun Pyo Kim1, Young Hee Jung8, 
Samuel Lockhart9, Rik Ossenkoppele10, Susan Landau11, Duk L. Na1,5,12, Michael Weiner13, 
Seonwoo Kim3* & Sang Won Seo1,5,14,15,16*
To characterize the course of Alzheimer’s disease (AD) over a longer time interval, we aimed to 
construct a disease course model for the entire span of the disease using two separate cohorts 
ranging from preclinical AD to AD dementia. We modelled the progression course of 436 patients 
with AD continuum and investigated the effects of apolipoprotein E ε4 (APOE ε4) and sex on disease 
progression. To develop a model of progression from preclinical AD to AD dementia, we estimated 
Alzheimer’s Disease Assessment Scale-Cognitive Subscale 13 (ADAS-cog 13) scores. When calculated 
as the median of ADAS-cog 13 scores for each cohort, the estimated time from preclinical AD to 
MCI due to AD was 7.8 years and preclinical AD to AD dementia was 15.2 years. ADAS-cog 13 scores 
deteriorated most rapidly in women APOE ε4 carriers and most slowly in men APOE ε4 non-carriers 
(p < 0.001). Our results suggest that disease progression modelling from preclinical AD to AD dementia 
may help clinicians to estimate where patients are in the disease course and provide information on 
variation in the disease course by sex and APOE ε4 status.
Understanding the course of disease progression across the whole Alzheimer’s disease (AD) continuum including 
preclinical AD, mild cognitive impairment (MCI) due to AD, and AD dementia will help in designing clinical 
trials to test preventative interventions. Some studies have investigated the progression in preclinical  AD1, MCI 
due to  AD2 and AD  dementia3 separately. However, their mean follow-up durations of 1.4–6.2 years were too 
short to understand the progression across the entire AD spectrum. Unfortunately, following a single cohort for 
several decades is difficult, though not impossible (as demonstrated in the Nun  Study4, Framingham  study5 etc.).
A potential approach would be to use cross-sectional and longitudinal data from many individuals across 
the disease spectrum from no AD pathology to AD dementia, to estimate a single disease progression model 
across. This method is advantageous, as it allows us to construct a disease course model for the whole-time span 
over a longer period using multiple separate cohorts. As far as we know, no such analysis has been used to the 
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study of AD progression. Successfully constructing a model of the entire AD spectrum would allow an analysis 
of potential covariates that have been suggested to influence the disease process.
In the present study, we developed a model of AD progression across its entire spectrum using two separate 
cohorts. To investigate whether sex and APOE ε4 influence rates of cognitive decline across the AD continuum, 
we also constructed the disease models by sex and APOE ε4.
Methods
Participants. All data used in the present study were obtained from the Alzheimer’s Disease Neuroimag-
ing Initiative (ADNI) website (http://www.adni-info.org) as of May 2017. ADNI is a multisite longitudinal bio-
marker study that has enrolled cognitively normal (CN), older individuals; people with early MCI (EMCI) and 
late MCI (LMCI) which are determined using the Wechsler Memory Scale Logical Memory II and people with 
early AD. EMCI defined as milder episodic memory impairment than the LMCI group. The present study con-
sisted of 1091 participants enrolled in the ADNI-1, ADNI-GO and ADNI-2 cohorts who had available data for 
ADAS-cog13 testing and had 18F-AV45 (Florbetapir) PET to assess amyloid-β (Aβ) deposition. According to 
the National Institute on Aging-Alzheimer’s Association  criteria6–8, Aβ (+) CN or subjective memory concerns 
(SMC) were defined as preclinical AD and Aβ (+) EMCI or LMCI were defined as MCI due to AD. In the present 
study, we included participants who were categorized as preclinical AD and MCI due to AD by their baseline 
diagnosis.
We excluded the following conditions: (1) 54 participants whose amyloid PET result changes; their amyloid 
PET result changed from positive to negative. (2) 40 participants in whom the ADAS-cog13 scores were obtained 
only once. Therefore, all enrolled participants performed ADAS-cog 13 at least two times. (3) 445 participants 
with amyloid pet negative result because amyloid negative CN could become amyloid positive then it is hard 
to make disease progression model with amyloid negative MCI. (4) 116 participants with dementia at baseline 
were not included because their median time of follow-up was short (12 months) and ADAS-cog 13 scores for 
AD dementia participant were in the range of ADAS-cog 13 scores for participants who progressed from MCI 
due to AD to AD dementia (Fig. 1)9.
All participants signed written informed consent at the time of enrolment. The authors obtained approval 
from the ADNI Data Sharing and Publications Committee for data use and publication. Since all the analyses 
were performed using de-identified ADNI data which is available for download, no IRB review was required. 
All methods were carried out in accordance with the approved guidelines.
Neuropsychological evaluation. For neuropsychological testing, participants undergo ADAS-Cog 13 
at baseline, 6, 12, and ongoing annually performed for CN, MCI participants. We used ADAS-cog 13, which 
includes tests of attention and concentration, planning and executive function, verbal memory, nonverbal mem-
ory, praxis, delayed word recall, and number cancellation or maze tasks. ADAS-cog 13 scores range from 0 to 
85. The ADAS-cog 13 is more responsive to disease progression than the ADAS-cog 11 in subjects with AD and 
similar or slightly more responsive in subjects with pre-dementia  syndromes10,11.
Image acquisition and processing. We downloaded amyloid (florbetapir) PET data from the ADNI 
website. Florbetapir imaging consisted of four 5-min frames (dynamic 3D scan) acquired 50–70  min after 
injection of 370  MBq (10  mCi) of tracer; frames were realigned, averaged, resliced to a common voxel size 
(1.5  mm × 1.5  mm × 1.5  mm) and smoothed to a common resolution of 8  mm3. MPRAGE images acquired 
concurrently with baseline florbetapir images and used as a structural template to define cortical and reference 
regions in native space for each subject with FreeSurfer. More detailed information can be found at http://www.
loni.ucla.edu. A florbetapir cortical summary measurement (SUVR) was calculated by dividing cortical uptake 
Figure 1.  Flow diagram for selection of the study participants. We excluded the following participants: (1) 
54 participants whose amyloid PET result changed from positive to negative; (2) 40 participants in whom 
ADAS-cog13 scores were obtained only once; (3) 445 participants with amyloid-negative PET results, because if 
amyloid-negative CN could become amyloid-positive, it would be difficult to create a disease progression model 
with amyloid-negative MCI; and (4) 116 participants with dementia at baseline, because their follow-up was 
short and the ADAS-cog 13 scores of AD dementia participants were in the range of the ADAS-cog 13 scores of 
participants who progressed from MCI due to AD to AD dementia. ADAS-cog: Alzheimer’s Disease Assessment 
Scale-cognitive subscale, CN: cognitive normal; MCI: mild cognitive impairment; AD: Alzheimer’s Disease.
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by a whole cerebellum as a reference region. We included only amyloid-positive individuals with an Amyloid 
SUVR of 1.1112 or higher in our analysis.
APOE genotyping. APOE genotyping was performed on DNA obtained from participant blood samples 
with an APOE genotyping kit as described at the ADNI site (see http://www.adni-info.org for detailed infor-
mation on blood sample collection, DNA preparation, and genotyping methods). APOE ε4 non-carriers were 
defined as no APOE ε4 allele and APOE ε4 carriers as one or two APOE ε4 alleles.
Statistical analysis. In order to model the disease progression course from preclinical AD to AD dementia 
using two cohorts, we carried out the following three processes: (1) modelling of ADAS-cog 13 scores for each 
cohort, (2) calculating the time for ADAS-cog 13 scores from the two cohorts to start to overlap, (3) construct-
ing an entire disease continuum model. First, for the estimation of the model for longitudinal data (Fig. 2a), the 
mixed-effects model with a random effect for the subject and a fixed effect for time was applied to each set of 
disease cohort data. In the development of the model, ADAS-cog 13 scores were square root–transformed due 
to a highly skewed distribution, and outliers with an absolute studentized residual larger than 3 were excluded 
(Fig. 2b). Second, using the estimated mixed effect model for each cohort, the estimate and 95% confidence 
interval (CI) for mean ADAS-cog 13 scores at the time were calculated. If a point estimate of mean ADAS-cog 13 
score in MCI due to AD fell within the 95% CI of mean ADAS-cog 13 scores in preclinical AD, that a mean esti-
mate was considered as an overlapped mean ADAS-cog 13 score between the two cohorts. We found the small-
est mean score among the overlapped mean ADAS-cog 13 scores in the MCI due to AD cohort and substituted 
this mean score into the estimated model for the preclinical AD cohort to calculate the corresponding time to 
this mean ADAS-cog13 score. This indicated the time from mean baseline ADAS13 for preclinical AD to mean 
baseline ADAS13 for MCI due to AD (Fig. 2c). Then, we shifted the MCI due to AD cohort data to start from 
that time (Fig. 2d). Finally, a single model for the entire course of AD was estimated by analysing data from the 
second step using a linear mixed effects model that included the same effect terms as the individual cohort mod-
els. In this model, the duration and its 95% CI for progression from preclinical AD to MCI due to AD and to AD 
dementia was calculated in terms of the time corresponding to the median ADAS-cog 13 scores and the 95% CI 
for the progressed groups (Fig. 3). To investigate the effect of sex and APOE ε4 status on ADAS-cog 13 decline, 
another progression model for the entire AD continuum was developed using a linear mixed effects model that 
included the combined effects of sex and APOE ε4 carrier status, as well as a time effect and a random intercept 
effect (Fig. 4). Model fit was investigated using the Akaike information criterion (AIC), Bayesian information 
criterion (BIC), and AIC with correction for finite sample size (AICC).
In a sensitivity analysis, we examined the learning effect and the effect of the different APOE ε4 allele distribu-
tions between the cohorts on the estimated results. We adjusted for learning effects (LEs), because LEs related 
to repeated measurements may obscure cognitive decline and delay the detection of conversion to  MCI13 and 
AD. The magnitude of LEs was estimated and tested with six alternative linear mixed models according to the 
covariates of age at baseline, sex, and education  level14. ADAS-cog 13 scores adjusted for LEs were used for the 
sensitivity analysis. We also performed frequency matching of APOE ε4 allele carriage for preclinical AD and 
MCI due to AD, and estimated the ADAS-cog 13 score and the corresponding time for the two cohorts to start 
to overlap using the matched data.
P-values were corrected for multiple testing using the Bonferroni method. Continuous and categorical vari-
ables were summarized as median (inter-quartile range (IQR, 1st quartile–3rd quartile) and frequency (percent-
age), respectively. A two-tailed P-value < 0.05 was considered to indicate statistical significance. The statistical 
analysis was performed with SAS 9.1.3 (SAS Institute Inc, Cary, NC, USA) and the R3.4.1 package (Vienna, 
Austria).
Results
Demographic and clinical characteristics of participants. The preclinical AD cohort included 127 
participants, while the MCI due to AD cohort included 309 participants (Table 1). The median age of partici-
pants with preclinical AD was 74.6 years (IQR 70.8–78.5), while that of participants with MCI due to AD was 
73.6 years (68.5–78.1). In the preclinical AD cohort and in the MCI due to AD cohort, 57 participants (44.9%) 
and 210 participants (68.0%) were APOE ε4 carriers, respectively. Women comprised 79 participants (62.2%) in 
the preclinical AD cohort, and 130 (42.1%) in the MCI due to AD cohort. The median years of education were 16 
for both the preclinical AD cohort and the MCI due to AD cohort. The number of visits (median (IQR)) per par-
ticipant was 5 (3–7) in the preclinical AD cohort and 6 (4–7) in the MCI due to AD cohort. The follow-up period 
was 48 (24–72) months in the preclinical AD cohort and 48 (36–60) months in the MCI due to AD cohort. The 
median (IQR) ADAS-cog 13 scores were 9.3 (6.7–12.0) in the preclinical AD cohort and 17 (12.0–21.0) in the 
MCI due to AD cohort. In the preclinical AD cohort, 37 participants (29.1%) progressed to MCI due to AD and 
13 (10.2%) progressed to AD dementia. In the MCI due to AD cohort, 134 participants (43.4%) progressed to 
AD dementia.
Disease progression modelling from preclinical AD to AD dementia. The median ADAS-cog 13 
score was 16.0 points at the time of progression for participants who progressed from preclinical AD to MCI due 
to AD and 26.8 points at the time of progression for participants who progressed from MCI due to AD to AD 
dementia. The estimated years (95% CI) for progression from the median ADAS-cog 13 score in the preclinical 
AD cohort (9.3 points) to the median ADAS-cog 13 at the time of progression in participants who progressed 
from preclinical AD to MCI due to AD (16.0 points) was 7.8 (6.1–10.0) years. The estimated years for progres-
sion from preclinical AD to the median ADAS-cog 13 at the time of progression in participants who progressed 
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Figure 2.  Modelling the course of Alzheimer’s disease using ADAS-cog 13 scores. (a) The pattern of individual 
ADAS-cog 13 scores in individuals with preclinical AD and MCI due to AD. (b) The estimated ADAS-cog 13 
scores over time for each subject and for each cohort, obtained from a linear mixed effects model with time 
as a fixed effect and subjects as a random effect (excluding outliers). Green and blue lines mean the estimated 
ADAS-cog 13 score for each subject at the time for preclinical AD and MCI due to AD, respectively. Black solid 
and dotted lines mean the estimate and 95% confidence interval (CI) for mean ADAS-cog 13 score at the time. 
(c) The estimated mean ADAS-cog 13 score and the corresponding time for two cohorts to start to overlap. 
Solid line means the estimated mean ADAS-cog 13 score and dotted lines mean 95% CI of the estimated mean 
ADAS-cog 13 score. (d) Scatter plot of the combined preclinical AD and MCI due to AD cohorts shifted by the 
time of 93.9 months, corresponding to an ADAS-cog 13 score of 15.8 points. ADAS-cog: Alzheimer’s Disease 
Assessment Scale-cognitive subscale, MCI: mild cognitive impairment; AD: Alzheimer’s Disease.
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from MCI due to AD to AD dementia (26.8 points) was 15.2 (14.1–15.9) years (Fig. 3). Additionally, when the 
calculation was performed using the median ADAS-cog 13 score for LMCI (19 points), the estimated time to 
progress from preclinical AD to LMCI was 8.9 years.
APOE ε4 effects on the course of disease progression by sex. We analysed the individual effect of 
sex and APOE ε4 on ADAS-cog 13 score change over time for each cohort. APOE ε4 carriers had a faster decline 
in ADAS-cog 13 score than APOE ε4 non-carriers in both cohorts (p = 0.0036 for preclinical AD, p < 0.0001 for 
MCI due to AD). Women had a steeper decline in ADAS-cog 13 score than men (p < 0.0001 for both cohorts). 
Then, to discover the combined effect of sex and APOE ε4 in the AD continuum, we analysed differences in the 
rate of cognitive decline stratified by sex and APOE ε4 status (Fig. 4). APOE ε4 carriers had a steeper decline 
in ADAS-cog 13 scores than did APOE ε4 non-carriers regardless of sex (p < 0.001). Women also had a steeper 
decline in ADAS-cog 13 scores than men, irrespective of APOE ε4 carrier status (p < 0.001). ADAS-cog 13 
scores deteriorated most rapidly for women APOE ε4 carriers and most slowly for men APOE ε4 non-carriers 
(p < 0.001). Using the median ADAS-cog13 values for participants with MCI due to AD who progressed to AD 
dementia, we calculated the time to progress from preclinical AD to AD dementia for four combinations of sex 
and APOE ε4 status (Table 2). We estimated that women APOE ε4 carriers with a median ADAS-cog 13 score 
(29 points) at the time of progression would take 11.5 (95% CI 10.0–11.9) years to progress to AD dementia. 
When estimated in the same way, men APOE ε4 carriers took 12.7 (10.5–14.0) years to progress from preclinical 
AD to AD dementia, while women APOE ε4 non-carriers took 20.2 (13.5–23.7) years and men APOE ε4 non-
carriers took 24.0 (17.7–30.9) years. In our disease model, we found that there were time differences between 
APOE ε4 carriers and non-carriers in baseline median ADAS-cog 13 in the MCI due to AD cohort: 3.9 years for 
women and 6.5 years for men (Fig. 4). More importantly, this difference started at the baseline median ADAS-
cog13 score for the preclinical AD cohort. To discover which model fit the data best, we performed goodness of 
fit test for models with and without sex and APOE ε4 (Supplementary Table S1). The model including sex and 
APOE ε4 was better than the model without those variables.
Sensitivity analysis. We performed frequency matching for APOE ε4 allele carriage between preclinical 
AD and MCI due to AD cohort, and calculated the time for a subject to convert from the preclinical to prodro-
mal stage to examine the effect of the different APOE4 ε4 allele distributions between preclinical AD and MCI 
Figure 3.  Disease progression model from preclinical AD to AD dementia. The curves present the estimated 
model—ADAS-cog 13 = (2.8492 + 0.0130 × month)2 – 0.5 and its 95% CI and the plots show preclinical AD 
(green dots), progression to MCI due to AD (yellow dots), MCI due to AD (blue dots), and progression to AD 
dementia (red dots). Using the median ADAS-cog 13 scores at the time of progression for individuals who 
progressed from preclinical AD to MCI due to AD (16.0 points) and from MCI due to AD to AD dementia 
(26.8 points), we estimated the time for preclinical AD to progress to MCI due to AD (7.8 years) and to AD 
dementia (15.2 years). When using the median ADAS-cog 13 scores for late MCI (19.0 points) to estimate 
time to progression, it took 8.9 years for preclinical AD to progress to late MCI. ADAS-cog: Alzheimer’s 




Scientific Reports |         (2021) 11:4168  | https://doi.org/10.1038/s41598-021-83585-3
www.nature.com/scientificreports/
due to AD cohorts on the estimated results (Supplementary Fig. S1). The matched data showed ADAS-cog 13 
score for the two cohorts at start of overlap was estimated as 15.1 (95% CI 14.1–16.2) and the corresponding 
time was 7.4 years (88.2 months, 95% CI 77.0–99.4).This result did not differ much from the result using the 
unmatched data (7.8 years, Fig. 3), but the time at which the two cohorts began to overlap was a little shorter in 
the matched data.
Figure 4.  Sex and APOE ε4 effects on disease progression. We analysed differences in cognitive decline by sex 
and APOE ε4 status. Different-coloured lines indicate women APOE ε4 carriers (red), women APOE ε4 non-
carriers (pink), men APOE ε4 carriers (dark blue) or men APOE ε4 non-carriers (light blue). The box plot shows 
the median value of ADAS-cog 13 was 9.3 for preclinical AD and 17.0 for MCI due to AD. The time differences 
between APOE ε4 carriers and non-carriers at baseline median ADAS-cog 13 in the MCI due to AD cohort 
(17.0 points) were 3.9 years for women (10.3 years (APOE ε4 non-carriers)—6.4 years (APOE ε4 carriers)) 
and 6.5 years for men (13.5 years (APOE ε4 non-carriers)—7.0 years (APOE ε4 carriers)). The estimated 
equation for each sex and APOE ε4 combination is as follows: ADAS Cog-13 = (2.6131 + 0.0203 × month)2 – 0.5 
for women APOE ε4 carriers, = (2.6842 + 0.0121 × month)2 – 0.5 for women APOE ε4 non-
carriers, = (3.1198 + 0.0127 × month)2 – 0.5 for men APOE ε4 carriers, = (3.0806 + 0.0068 × month)2 – 0.5 for 
men APOE ε4 non-carriers. ADAS-cog: Alzheimer’s Disease Assessment Scale-cognitive subscale; APOE: 
Apolipoprotein E.
Table 1.  Demographics and clinical features of participants with AD. Age, education, ADAS-cog 13 and 
month of follow-up are expressed as median (IQR). Categorical variables are expressed as no (%). Statistical 
analyses are performed with Chi-squared tests for APOEε4 carriers and sex. Mann Whitney test for age, 
education and ADAS-cog 13. AD: Alzheimer’s disease; ADAS-cog: Alzheimer’s disease assessment scale-
cognitive subscale; APOE: apolipoprotein E; IQR: interquartile range; MCI: mild cognitive impairment. 
*p < 0.05 between preclinical AD vs. MCI due to AD.
Diagnosis Preclinical AD MCI due to AD
Participants no. (%) 127 (29.2) 309 (70.9)
Age (year), median (IQR) 74.6 (70.8–78.5) 73.6 (68.5–78.1)
APOE ε4 carriers, no. (%) 57 (44.9)* 210 (68.0)*
Women, no. (%) 79 (62.2)* 130 (42.1)*
Education (year), median (IQR) 16 (14–18) 16 (14–18)
Follow up
Number of visits per participant, median (IQR) 5 (3–7) 6 (4–7)
Follow up month, median (IQR) 48 (24–72) 48 (36–60)
ADAS-cog 13
Median (IQR) 9.3 (6.7–12.0)* 17 (12.0–21.0)*
Conversion to
MCI due to AD, no (%) 37 (29.1)
AD dementia, no (%) 13 (10.2) 134 (43.4)
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Additionally, we performed an analysis for LEs to investigate the robustness of LEs. LEs were significant and 
were estimated to affect a given ADAS-cog 13 score by − 0.52 for preclinical AD and by − 0.54 for MCI due to 
AD in all models (Supplementary Table S2). After correcting for LEs and repeating the analyses, we estimated 
the disease progression course from preclinical AD to AD dementia according to ADAS-cog 13 scores. The esti-
mated times for preclinical AD to progress to MCI due to AD and to AD dementia were 6.7 (95% CI, 5.0–9.0) 
and 14.2 (13.1–14.9) years based on median ADAS-cog 13 scores (supplementary Fig. S2). When we analysed 
differences in the rate of cognitive decline based on a combination of sex and APOE ε4 status after correcting 
for LEs (supplementary Fig. S3), the progression order and significant differences among groups did not change 
compared to the analysis of data uncorrected for LE.
Discussion
In the present study, using two separate cohorts, we modelled disease progression from preclinical AD to AD 
dementia and determined whether APOE ε4 status and sex affected progression across the entire AD spectrum. 
Our main findings were as follows. Our novel disease progression model indicated that it would take 7.8 years 
for preclinical AD to progress to MCI due to AD and 15.2 years to progress to AD dementia based on median 
ADAS-cog 13 scores. APOE ε4 carriers and women had worse cognitive trajectories across the entire AD spec-
trum. Across all sex and APOE ε4 combinations, women APOE ε4 carriers had the fastest cognitive decline. 
Taken together, our findings provide a further understanding of AD progression across the disease spectrum, 
and they will help to design individualized therapeutic and preventive strategies to ameliorate cognitive decline.
We modelled the AD disease progression course using two different cohorts and estimated that it took almost 
15 years for preclinical AD to progress to AD dementia. In a recent  article15, 14.5% of individuals with preclini-
cal AD developed incident MCI due to AD within a 3.7 year (mean) follow-up period, and 3.2% developed AD 
dementia within 4.2 years of follow-up15. Additionally, studies have found that 32.7%15 and 70.0%16 of individuals 
with MCI due to AD developed AD dementia within 3.2 and 3.6 years of follow-up,  respectively15,16. However, 
2–4 years of follow-up may not be sufficient to estimate the entire course of disease progression. These previous 
findings, thus, mainly characterize fast decliners in each disease stage. However, our estimated course is con-
sistent with indirect evidence provided in previous  studies6,17, according to which the temporal lag between Aβ 
deposition and the clinical syndrome of AD dementia was a  decade6. In a meta-analysis, age-related increases 
in amyloid positivity on PET in participants with normal cognition paralleled age-specific, AD-type dementia 
prevalence estimates with an intervening period of about 20  years17,18. Another study estimated that it took 
19.2 years for 11C-PiB levels observed in healthy controls with a 1.5 SUVR threshold to reach the mean SUVR 
of AD (2.3)19. Our finding that it would take more than 15 years for preclinical AD to progress to AD dementia 
suggests that appropriate interventions are needed to prevent preclinical AD from progressing to AD dementia.
In the present study, the estimated time from the preclinical to prodromal stage (7.8 years) was similar to 
that from the prodromal to the dementia stage (7.4 years). Initially, we expected that the preclinical phase might 
be longer than the prodromal phase. Our findings might have been related to our definition of the prodromal 
phase using the early stage of MCI. If we define MCI due to AD as LMCI, the estimated time from preclinical AD 
to LMCI (8.9 years) would be longer than that from MCI due to AD to AD dementia (6.3 years). Alternatively, 
the study design—in particular, whether a study includes volunteer or clinic-based participants—might affect 
time-to-event estimates. For example, studies may overestimate the progression rate in the presymptomatic 
phase because the included participants might have more concerns about their cognition. Our disease progres-
sion model could be used to estimate the current and future state of preclinical AD patients in a prevention trial.
Another main finding is that sex and APOE ε4 had distinct effects on the progression course across the AD 
continuum. Our finding that APOE ε4 aggravated cognitive decline across the entire AD spectrum regardless 
of sex is partially consistent with previous studies. While APOE ε4 is a well-known risk factor for AD dementia 
in the preclinical or prodromal  stage20, it has been debated whether APOE ε4 predicts a worse  prognosis21,22. A 
previous study by our group revealed that APOE ε4 predicted more rapid hippocampal and cortical atrophy in 
dementia with  AD21. However, other studies have suggested that AD patients with APOE ε4 had a lower global 
amyloid burden than matched APOE ε4 non-carriers22–24. This discrepancy might be due to differences in the 
study populations (patients who progressed to AD dementia over time in the current study sample compared to 
patients who had already progressed to AD dementia in previous studies).
Table 2.  Estimated time to reach AD dementia depending on APOE ε4 status by sex. We assigned the 
median ADAS-cog 13 score at the point of conversion from MCI due to AD to AD dementia to the equation 
for each sex and APOE ε4 combination to obtain the estimated converting year to AD dementia. ADAS-cog: 
Alzheimer’s disease assessment scale-cognitive subscale; APOE: apolipoprotein E; IQR: interquartile range; 
CI: confidence interval. a ADAS-cog 13 median (IQR) at the point of conversion from MCI due to AD to AD 






Women APOE ε4 carriers 44 29 (23.5–33.0) 11.5 (10.0–11.9)
Men APOE ε4 carriers 57 25 (20.0–31.0) 12.7 (10.5–14.0)
Women APOE ε4 non-carriers 14 31 (23.0–34.0) 20.2 (13.5–23.7)
Men APOE ε4 non-carriers 19 25 (20.0–31.0) 24.0 (17.7–30.9)
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A more noteworthy finding that women APOE ε4 carriers showed more prominent cognitive decline than 
did men APOE ε4 carriers across the AD  spectrum25,26. Our findings are consistent with a previous  study25, 
which showed that women with higher Aβ levels had a faster cognitive decline than men and that women with 
preclinical AD who were APOE ε4 carriers declined faster than their men counterparts. However, the previous 
findings were not statistically significant after correction for multiple  comparisons25. Our findings further sug-
gest that women APOE ε4 carriers had a steeper cognitive decline than did men APOE ε4 carriers throughout 
the entire AD spectrum. Therefore, developing a progression model stratified by these factors will help to select 
cohorts for AD clinical trials.
Several possible explanations may account for the combined effects of sex and  APOE27–30. A potential mecha-
nism could be that oestradiol promotes synaptic sprouting in response to injury through an APOE-dependent 
 mechanism27. Additionally, oestrogen might promote neural function under normal conditions, but exacerbate 
dysfunction when network activity is  disrupted28. Alternatively, a previous study showed that the APOE ε4-by-
sex interaction on cerebrospinal fluid (CSF) tau levels were significant, suggesting that the increased APOE-
related risk in women may be associated with tau  pathology29. In a recent multicohort  study30, women showed 
a stronger association between APOE and CSF tau levels than did men, particularly among amyloid-positive 
individuals, suggesting that APOE may modulate the risk of downstream neurodegeneration in a sex-specific 
manner, particularly in the presence of amyloidosis.
The ADNI is a well-organized, longitudinal cohort that serves as an excellent resource to investigate the dis-
ease course of AD. This study, however, has several limitations. We only included participants who were amyloid-
positive by PET. This leaves open the possibility that some patients had another primary pathological diagnosis. 
Although participants clinically diagnosed with frontotemporal dementia or dementia with Lewy bodies and who 
had moderate to severe white matter hyperintensity were excluded from the ADNI dataset, we did not consider 
the effects of other neurodegenerative pathologies, including cerebrovascular disease, α-synuclein, transactive 
response DNA-binding protein, argyrophilic grain pathology, and hippocampal sclerosis, on the progression 
model. Importantly, amyloid positivity might only be a contributing or incidental factor in some patients with 
dementia. This argument is mitigated to some degree by the fact that we included participants who progressed 
from MCI due to AD to AD dementia. Additionally, we found that the ADAS-cog 13 scores in some participants 
with CN and MCI improved over time. Although we controlled for LEs, we did not completely exclude the pos-
sibility that LEs might affect the disease progression to some degree.
Nevertheless, ADAS-cog 13 is the standard tool used in many clinical trials to assess AD, which makes our 
results more interpretable across studies than if we had used another instrument. Finally, our progression rate 
from NC to MCI (29.1%) was higher than has been observed in community-recruited older adults. For example, 
a greater risk of progression from NC to MCI was observed in clinically-recruited older adults (30% per year) 
than in community-recruited older adults (5% per year)31. The ADNI used identical recruitment mechanisms 
to those of typical trials, including advertising and recruitment from memory clinics. Although our data might 
not be representative of the general population, the recruitment and subject baseline characteristics were similar 
to those of a typical AD clinical trial.
In the current study, we found that our model of the progression to disease may help clinicians to predict 
where patients are in the disease course. In addition, it will help to predict how the disease course could vary 
by sex and APOE ε4 status when consulting with patients and predicting treatment effects. Understanding 
the natural history of AD and the rates of change of clinical phenotypes and biomarkers will facilitate specific 
appropriate interventions.
Data availability
All raw data are available on the ADNI website. Anonymized and statistical information of all the participants 
are available, upon reasonable request only among qualified investigators.
Received: 23 January 2020; Accepted: 29 January 2021
References
 1. Donohue, M. C. et al. Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal 
persons. JAMA 317, 2305–2316. https ://doi.org/10.1001/jama.2017.6669 (2017).
 2. Ward, A., Tardiff, S., Dye, C. & Arrighi, H. M. Rate of conversion from prodromal Alzheimer’s disease to Alzheimer’s dementia: 
A systematic review of the literature. Dement. Geriatr. Cogn. Dis. Extra 3, 320–332. https ://doi.org/10.1159/00035 4370 (2013).
 3. Cho, H. et al. Longitudinal changes of cortical thickness in early-versus late-onset Alzheimer’s disease. Neurobiol. Aging 34, 1921.
e9. https ://doi.org/10.1016/j.neuro biola ging.2013.01.004 (2013).
 4. Snowdon, D. A. & Nun, S. Healthy aging and dementia: Findings from the Nun Study. Ann. Intern. Med. 139, 450–454 (2003).
 5. Wolf, P. A. Contributions of the Framingham Heart Study to stroke and dementia epidemiologic research at 60 years. Arch. Neurol. 
69, 567–571. https ://doi.org/10.1001/archn eurol .2011.977 (2012).
 6. Sperling, R. A. et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute 
on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 7, 280–292. 
https ://doi.org/10.1016/j.jalz.2011.03.003 (2011).
 7. Albert, M. S. et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National 
Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 7, 
270–279. https ://doi.org/10.1016/j.jalz.2011.03.008 (2011).
 8. McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on 
Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 7, 263–269. 
https ://doi.org/10.1016/j.jalz.2011.03.005 (2011).
 9. Aisen, P. S., Petersen, R. C., Donohue, M., Weiner, M. W. & Alzheimer’s Disease Neuroimaging, I. Alzheimer’s disease neuroimaging 
initiative 2 clinical core: Progress and plans. Alzheimers Dement. 11, 734–739. https ://doi.org/10.1016/j.jalz.2015.05.005 (2015).
9
Vol.:(0123456789)
Scientific Reports |         (2021) 11:4168  | https://doi.org/10.1038/s41598-021-83585-3
www.nature.com/scientificreports/
 10. Skinner, J. et al. The Alzheimer’s Disease Assessment Scale-Cognitive-Plus (ADAS-Cog-Plus): An expansion of the ADAS-Cog to 
improve responsiveness in MCI. Brain Imaging Behav. 6, 489–501. https ://doi.org/10.1007/s1168 2-012-9166-3 (2012).
 11. Mohs, R. C. et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: Additions to the Alzhei-
mer’s Disease Assessment Scale that broaden its scope. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis. Assoc. Disord. 
11(Suppl 2), S13–S21 (1997).
 12. Landau, S. M. et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann. Neurol. 72, 578–586. https ://
doi.org/10.1002/ana.23650 (2012).
 13. Elman, J. A. et al. Underdiagnosis of mild cognitive impairment: A consequence of ignoring practice effects. Alzheimers Dement. 
10, 372–381. https ://doi.org/10.1016/j.dadm.2018.04.003 (2018).
 14. Vivot, A. et al. Jump, hop, or skip: Modeling practice effects in studies of determinants of cognitive change in older adults. Am. J. 
Epidemiol. 183, 302–314. https ://doi.org/10.1093/aje/kwv21 2 (2016).
 15. Roberts, R. O. et al. Prevalence and outcomes of amyloid positivity among persons without dementia in a longitudinal, population-
based setting. JAMA Neurol. 75, 970–979. https ://doi.org/10.1001/jaman eurol .2018.0629 (2018).
 16. Ye, B. S. et al. Longitudinal outcomes of amyloid positive versus negative amnestic mild cognitive impairments: A three-year 
longitudinal study. Sci. Rep. 8, 5557. https ://doi.org/10.1038/s4159 8-018-23676 -w (2018).
 17. Jansen, W. J. et al. Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis. JAMA 313, 1924–1938. 
https ://doi.org/10.1001/jama.2015.4668 (2015).
 18. Jansen, W. J. et al. Association of cerebral amyloid-beta aggregation with cognitive functioning in persons without dementia. JAMA 
Psychiatry 75, 84–95. https ://doi.org/10.1001/jamap sychi atry.2017.3391 (2018).
 19. Villemagne, V. L. et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: A 
prospective cohort study. Lancet Neurol. 12, 357–367. https ://doi.org/10.1016/S1474 -4422(13)70044 -9 (2013).
 20. Farrer, L. A. et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. 
A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278, 1349–1356 (1997).
 21. Kim, Y. J. et al. Apolipoprotein e4 affects topographical changes in hippocampal and cortical atrophy in Alzheimer’s disease 
dementia: A five-year longitudinal study. J. Alzheimers Dis. 44, 1075–1085. https ://doi.org/10.3233/JAD-14177 3 (2015).
 22. Lehmann, M. et al. Greater medial temporal hypometabolism and lower cortical amyloid burden in ApoE4-positive AD patients. 
J. Neurol. Neurosurg. Psychiatry 85, 266–273. https ://doi.org/10.1136/jnnp-2013-30585 8 (2014).
 23. Rowe, C. C. et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol. 
Aging 31, 1275–1283. https ://doi.org/10.1016/j.neuro biola ging.2010.04.007 (2010).
 24. Ossenkoppele, R. et al. Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia. Neurology 
80, 359–365. https ://doi.org/10.1212/WNL.0b013 e3182 7f088 9 (2013).
 25. Buckley, R. F. et al. Sex, amyloid, and APOE epsilon4 and risk of cognitive decline in preclinical Alzheimer’s disease: Findings 
from three well-characterized cohorts. Alzheimers Dement. 14, 1193–1203. https ://doi.org/10.1016/j.jalz.2018.04.010 (2018).
 26. Lin, K. A. et al. Marked gender differences in progression of mild cognitive impairment over 8 years. Alzheimers Dement. 1, 
103–110. https ://doi.org/10.1016/j.trci.2015.07.001 (2015).
 27. Stone, D. J., Rozovsky, I., Morgan, T. E., Anderson, C. P. & Finch, C. E. Increased synaptic sprouting in response to estrogen via an 
apolipoprotein E-dependent mechanism: implications for Alzheimer’s disease. J. Neurosci. 18, 3180–3185. https ://doi.org/10.1523/
jneur osci.18-09-03180 .1998 (1998).
 28. Broestl, L. et al. Ovarian cycle stages modulate Alzheimer-related cognitive and brain network alterations in female mice. eNeuro 
https ://doi.org/10.1523/ENEUR O.0132-17.2018 (2018).
 29. Altmann, A., Tian, L., Henderson, V. W. & Greicius, M. D. Sex modifies the APOE-related risk of developing Alzheimer disease. 
Ann. Neurol. 75, 563–573. https ://doi.org/10.1002/ana.24135 (2014).
 30. Hohman, T. J. et al. Sex-specific association of apolipoprotein E with cerebrospinal fluid levels of tau. JAMA Neurol. 75, 989–998. 
https ://doi.org/10.1001/jaman eurol .2018.0821 (2018).
 31. Chen, Y. et al. Progression from normal cognition to mild cognitive impairment in a diverse clinic-based and community-based 
elderly cohort. Alzheimers Dement. 13, 399–405. https ://doi.org/10.1016/j.jalz.2016.07.151 (2017).
Acknowledgements
This research was supported by the Brain Research Program through the National Research Foundation of Korea 
(NRF) funded by the Ministry of Science, ICT & Future Planning (2016M3C7A1913844), National Research 
Council of Science & Technology (NST) grant by the Korea government (MSIP) (No. CRC-15-04-KIST), grant 
of the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI18C0335, 
HI19C1132) and Chonnam National University Hospital Biomedical Research Institute (BCRI20012). Data 
used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) 
database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and imple-
mentation of ADNI and/or provided data but did not participate in analysis or writing of this report. A com-
plete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-conte nt/uploa ds/how_to_apply 
/ADNI_Ackno wledg ement _List.pdf.
Author contributions
S.H.C., S.Y.W., S.K. and S.W.S. contributed to the study conception, design of the study, data analysis, data inter-
pretation and drafting. C.K., H.J.K., H.M.J., B.C.K., S.E.K., S.J.K., J.P.K., Y.H.J. and D.L.N. contributed to data 
interpretation. S.L., R.O., S.L. and M.W. drafted the manuscript.
Competing interests 
The authors declare no competing interests.
Additional information
Supplementary Information The online version contains supplementary material available at https ://doi.
org/10.1038/s4159 8-021-83585 -3.
Correspondence and requests for materials should be addressed to S.K. or S.W.S.
Reprints and permissions information is available at www.nature.com/reprints.




Scientific Reports |         (2021) 11:4168  | https://doi.org/10.1038/s41598-021-83585-3
www.nature.com/scientificreports/
Open Access  This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the 
Creative Commons licence, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from 
the copyright holder. To view a copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
© The Author(s) 2021
